Drug Delivery: What The Future Holds - - BioPharm International


Drug Delivery: What The Future Holds

BioPharm International
Volume 20, Issue 8

Approaches to BBB delivery include using lipophilic pro-drugs, carrier-mediated transport, inhibition of efflux transporters, and receptor-mediated transport.41 Given the importance of the CNS area, advances in BBB delivery should have significant impacts on the practice of medicine.

[Editors note: Figures for this article are not available online. To obtain a complete copy of the article with figures, please send your mailing address to

William J. Lambert, PhD, is the senior vice president of pharmaceutical development at Pacira Pharmaceuticals, Inc. (previously SkyePharma Inc.), San Diego, CA, 858.625.2424,


1. Hisey T. The big squeeze: The simple answer to pharma's pipeline crisis? Get more value out of the products you already have (lifecycle management). Pharm Exec. 2004 Oct; 24(10):86–98.

2. Downes Z. The World Biotech Market 2005. [report on the Internet]. Dorset, UK: Bioportfolio Limited; 2005 Jun 17. [cited 2007 July 17]. Available from: http://www.bioportfolio.com/cgi-bin/acatalog/The_World_Biotech_Market_2005.html,

3. Charman WN, Porter CJH, Mithani S, Dressman JB. Physicochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. J Pharm Sci. 1997;86(3):269–282.

4. Lee VHL, Yamamoto A. Penetration and enzymatic barriers to peptide and protein absorption. Adv Drug Delivery Rev. 1990;4:171–207.

5. Burton PS, Conradi RA, Ho,NFH, Hilgers AR, Borchardt RT. How structural features influence the biomembrane permeability of peptides. J Pharm Sci. 1996;85(12):1336–1340.

6. Rave et al., Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin.Diabetes Care. 2005;28:1077–1082.

7. Grundy GS, Foster RT. The nifedipine gastrointestinal therapeutic system (GITS). Clin Pharmacokinet. 1996;30(1) 28–51.

8. Zisson A. Wall Street's view of protein and peptide delivery: does this model still work? Amer Pharm Rev. 2003;6(3):21–24.

9. Martin NE, Collison KR, Martin LL, Tardif S, Wilding I, Wray H, Barrett JS. Pharmacoscintigraphic assessment of the regional drug absorption of the dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, M100240, in healthy volunteers. J Clin Pharmacol. 2003;43:529–538.

10. Rocca JG, Omidian H, Shah KU. Commercial status of gastric retention technologies. Drug Deliv Technol. 2005;5(4):50–58.

11. Sica DA, Neutel JM, Weber MA, Manowitz N. The antihypertensive efficacy and safety of a chronotherapeutic formulation of propranolol in patients with hypertension. J Clin. Hypertension 2004;6(5):231–241.

12. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413–420.

13. Lipka E, Crison J, Amidon GL. Transmembrane transport of peptide type compounds: prospects for oral delivery. J Control Release. 1996;39(2–3):121–9.

14. Lipinski, CA, Lombardo, F, Dominy, BW, Feeney, PJ, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Adv Drug Del Rev. 2001;46(1–3):3–26.

15. Patel MV, Chen F-J. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions. United States Patent 6,248,363, 2001 June 19 .

blog comments powered by Disqus



GPhA Issues Statement on Generic Drug Costs
November 20, 2014
Amgen Opens Single-Use Manufacturing Plant in Singapore
November 20, 2014
Manufacturing Issues Crucial to Combating Ebola
November 20, 2014
FDA Requests Comments on Generic Drug Submission Criteria
November 20, 2014
USP Joins Chinese Pharmacopoeia Commission for Annual Science Meeting
November 20, 2014
Author Guidelines
Source: BioPharm International,
Click here